Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pemetrexed-based chemotherapy provides QOL benefits similar to gemcitabine-based chemotherapy in patients with non-small cell lung cancer (NSCLC),

    • 11 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Eli Lilly and Company.Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer. Media Release: 2 Jun 2007. Available from: URL: http://www.lilly.com

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Pemetrexed-based chemotherapy provides QOL benefits similar to gemcitabine-based chemotherapy in patients with non-small cell lung cancer (NSCLC),. Pharmacoecon. Outcomes News 530, 10 (2007). https://doi.org/10.2165/00151234-200705300-00032

    Download citation

    Keywords

    • Lung Cancer
    • Health Outcome
    • Thrombocytopenia
    • Gemcitabine
    • Carboplatin